ALK and non-small cell lung carcinoma: For example, oligoprogression is well documented during treatment of onco-addicted NSCLC (ALK gene rearrangements or EGFR mutations) with TKIs such as crizotinib for ALK+ and erlotinib for EGFR mutated NSCLC.